Production (Stage)
Carisma Therapeutics, Inc.
CARM
$0.4297
-$0.0219-4.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.73M | 3.65M | 3.39M | 9.20M | 3.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.73M | 3.65M | 3.39M | 9.20M | 3.40M |
| Cost of Revenue | 9.16M | 15.58M | 11.33M | 15.31M | 17.46M |
| Gross Profit | -5.43M | -11.93M | -7.94M | -6.11M | -14.07M |
| SG&A Expenses | 3.91M | 3.93M | 5.20M | 5.56M | 5.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.06M | 19.51M | 16.53M | 20.87M | 22.91M |
| Operating Income | -9.33M | -15.86M | -13.14M | -11.67M | -19.51M |
| Income Before Tax | -9.27M | -17.64M | -12.70M | -11.16M | -18.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.27M | -17.64M | -12.70M | -11.16M | -18.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.27M | -17.64M | -12.70M | -11.16M | -18.98M |
| EBIT | -9.33M | -15.86M | -13.14M | -11.67M | -19.51M |
| EBITDA | -8.67M | -15.19M | -12.41M | -11.42M | -17.82M |
| EPS Basic | -0.22 | -0.42 | -0.31 | -0.27 | -0.46 |
| Normalized Basic EPS | -0.14 | -0.23 | -0.19 | -0.17 | -0.29 |
| EPS Diluted | -0.22 | -0.42 | -0.31 | -0.27 | -0.46 |
| Normalized Diluted EPS | -0.14 | -0.23 | -0.19 | -0.17 | -0.29 |
| Average Basic Shares Outstanding | 41.77M | 41.75M | 41.59M | 41.54M | 40.94M |
| Average Diluted Shares Outstanding | 41.77M | 41.75M | 41.59M | 41.54M | 40.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |